Laboratorios Farmaceuticos ROVI

Laboratorios Farmaceuticos ROVI Tangible Book Value per Share

The Tangible Book Value per Share of Laboratorios Farmaceuticos ROVI (ROVI.MC) as of Oct 25, 2026 is 12.92 EUR. In the previous year, Tangible Book Value per Share was 10.51 EUR — a change of 22.98% (higher).

Tangible Book Value per Share

12.92EUR

YoY

22.98%

Last updated:

Tangible Book Value per Share of Laboratorios Farmaceuticos ROVI is 2025 12.92 EUR. Tangible Book Value per Share of Laboratorios Farmaceuticos ROVI was 2024 10.51 EUR. It decreases by 22.98% higher compared to the previous year.

The Laboratorios Farmaceuticos ROVI Tangible Book Value per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Tangible Book Value per Share
Date
Tangible Book Value per Share
Jan 1, 2018
4.94 EUR
Jan 1, 2019
5.42 EUR
Jan 1, 2020
6.49 EUR
Jan 1, 2021
8.44 EUR
Jan 1, 2022
9.46 EUR
Jan 1, 2023
9.87 EUR
Jan 1, 2024
10.51 EUR
Jan 1, 2025
12.92 EUR
The Laboratorios Farmaceuticos ROVI Tangible Book Value per Share history
YEARTangible Book Value per ShareYoY
12.92EUR+22.98%
10.51EUR+6.45%
9.87EUR+4.38%
9.46EUR+11.99%
8.44EUR+30.13%
6.49EUR+19.83%
5.42EUR+9.68%
4.94EUR+53.59%
3.21EUR+3.83%
3.10EUR+8.66%
2.85EUR+3.28%
2.76EUR+5.89%
2.61EUR+4.88%
2.48EUR+10.92%
2.24EUR+9.33%
2.05EUR+18.34%
1.73EUR+26.25%
1.37EUR+33.89%
1.02EUR+28.00%
0.80EUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Laboratorios Farmaceuticos ROVI Stock analysis

What does Laboratorios Farmaceuticos ROVI do? Laboratorios Farmaceuticos ROVI SA is a Spanish pharmaceutical company that was founded in 1946 by Salvador and Ignacio Ruiz-Salmones. The company is headquartered in Madrid and employs over 1,000 employees. ROVI manufactures a variety of pharmaceutical products and offers services in various areas. The company specializes in the development and manufacturing of specialty preparations in the fields of oncology, hematology, endocrinology, and gastroenterology. The company operates in three business areas: specialty pharmaceuticals, contrast agents, and active ingredients for the industry. The specialty pharmaceuticals business area includes medications for various applications, such as the treatment of cancer, blood disorders, endocrine disorders, gastroenterological disorders, and central nervous system disorders. The contrast agents division produces products for radiology and diagnostics. The products are used in various medical fields, from cardiology to gastroenterology. In the active ingredients for the industry business area, ROVI manufactures active ingredients for other pharmaceutical companies. ROVI specializes in the production of specialty products and relies on collaborations with other companies. The company has strategic partnerships with many companies such as GlaxoSmithKline, Pfizer, Sanofi-Aventis, and Zeltia. This also includes some research collaborations to develop and market products together. The company is also dedicated to the development of biosimilars, which allow for the offering of biologic drugs at a lower price. Biosimilars are copies of biopharmaceuticals that are usually very expensive due to the complex manufacturing process and high development costs. ROVI is also a major producer of vaccines that are distributed worldwide. ROVI has followed a solid growth trajectory in recent years. The company has been able to consistently increase its revenue and profit and is now a major player in the pharmaceutical industry. The company also operates a strong research and development department that constantly develops new products and technologies to improve patient care. In summary, Laboratorios Farmaceuticos ROVI SA is a leading pharmaceutical company specializing in the manufacturing of specialty products. With its subsidiaries in Europe and the USA, ROVI has an international presence and has made a name for itself through its expertise in the development and manufacturing of innovative pharmaceutical products. Laboratorios Farmaceuticos ROVI is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Laboratorios Farmaceuticos ROVI stock

Tangible Book Value per Share of Laboratorios Farmaceuticos ROVI is 12.92 EUR in 2025.

Tangible Book Value per Share of Laboratorios Farmaceuticos ROVI changed from 10.51 EUR to 12.92 EUR, representing a 22.98% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Tangible Book Value per Share Laboratorios Farmaceuticos ROVI since 2006 – with annual values, charts, and detailed analysis.

Tangible book value per share excludes intangible assets and goodwill, providing a more conservative measure of per-share net asset value.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Laboratorios Farmaceuticos ROVI

All Key Metrics — Laboratorios Farmaceuticos ROVI